




FIG. 1




FIG. 2




FIG. 3




FIG. 4

```

mesrgrrcpe misvlgpisg hvlkavfsrg dtpvlphetr llqtfighvrq sqpslilvsq
ytpdstpchr gdnqlqvqht yftgsevenv svnvhnptgr sicpsqepms iyvyalplkm
lnipsinvhh ypsaaerkhr hlpvadavih asgkqmwqar ltvsglawtr qqngwkepdv
yytsafvfpt kdvalrhvvc ahelvcsmen tratkmqvig dqyvkvytes fcedvpsgkl
fmhvtlgsdv eedltmtrnp qpfrmrphern gftvlcpkrm iikpgkishi mldvaftshe
hfgllcpksi pglsgnll mngqqiflev qairetvelr qydpvaalff fdidlllgrg
pqysehtftt sqyriqqkle yrhtwdrhde gaaqgdddvw tsgsdsdeel vtterktprv
tgggamagas tsagrkrksa ssatactagv mtrgrlkaes tvapeedtde dsdneihnpa
vftwppwqag ilarnlvpmv atvqgqnlky qeffwdandi yrifaelegv wqpaaqpkrr
rhrqdalpgp ciastpkkhr g

```

Fig. 5

SEQUENCE LISTING

<110> Vakzine Projekt Management GmbH

<120> Viral particle released after infection of mammalian cells by human cytomegalovirus (HCMV) containing a fusion protein and use thereof

<130> SG3454A

<150> EP10003712.6

<151> 2010-04-06

<160> 1

<170> PatentIn version 3.3

<210> 1

<211> 561

<212> PRT

<213> Artificial

<220>

<223> synthetic

<400> 1

Met	Glu	Ser	Arg	Gly	Arg	Arg	Cys	Pro	Glu	Met	Ile	Ser	Val	Leu	Gly
1				5					10					15	

Pro	Ile	Ser	Gly	His	Val	Leu	Lys	Ala	Val	Phe	Ser	Arg	Gly	Asp	Thr
			20					25					30		

Pro	Val	Leu	Pro	His	Glu	Thr	Arg	Leu	Leu	Gln	Thr	Phe	Ile	His	Val
		35					40					45			

Arg	Val	Ser	Gln	Pro	Ser	Leu	Ile	Leu	Val	Ser	Gln	Tyr	Thr	Pro	Asp
	50					55					60				

Ser	Thr	Pro	Cys	His	Arg	Gly	Asp	Asn	Gln	Leu	Gln	Val	Gln	His	Thr
65					70					75				80	

Tyr	Phe	Thr	Gly	Ser	Glu	Val	Glu	Asn	Val	Ser	Val	Asn	Val	His	Asn
			85					90						95	

Pro	Thr	Gly	Arg	Ser	Ile	Cys	Pro	Ser	Gln	Glu	Pro	Met	Ser	Ile	Tyr
			100					105					110		

Val	Tyr	Ala	Leu	Pro	Leu	Lys	Met	Leu	Asn	Ile	Pro	Ser	Ile	Asn	Val
		115					120					125			

His His Tyr Pro Ser Ala Ala Glu Arg Lys His Arg His Leu Pro Val
130 135 140

Ala Asp Ala Val Ile His Ala Ser Gly Lys Gln Met Trp Gln Ala Arg
145 150 155 160

Leu Thr Val Ser Gly Leu Ala Trp Thr Arg Gln Gln Asn Gln Trp Lys
165 170 175

Glu Pro Asp Val Tyr Tyr Thr Ser Ala Phe Val Phe Pro Thr Lys Asp
180 185 190

Val Ala Leu Arg His Val Val Cys Ala His Glu Leu Val Cys Ser Met
195 200 205

Glu Asn Thr Arg Ala Thr Lys Met Gln Val Ile Gly Asp Gln Tyr Val
210 215 220

Lys Val Tyr Leu Glu Ser Phe Cys Glu Asp Val Pro Ser Gly Lys Leu
225 230 235 240

Phe Met His Val Thr Leu Gly Ser Asp Val Glu Glu Asp Leu Thr Met
245 250 255

Thr Arg Asn Pro Gln Pro Phe Met Arg Pro His Glu Arg Asn Gly Phe
260 265 270

Thr Val Leu Cys Pro Lys Asn Met Ile Ile Lys Pro Gly Lys Ile Ser
275 280 285

His Ile Met Leu Asp Val Ala Phe Thr Ser His Glu His Phe Gly Leu
290 295 300

Leu Cys Pro Lys Ser Ile Pro Gly Leu Ser Ile Ser Gly Asn Leu Leu
305 310 315 320

Met Asn Gly Gln Gln Ile Phe Leu Glu Val Gln Ala Ile Arg Glu Thr
325 330 335

Val Glu Leu Arg Gln Tyr Asp Pro Val Ala Ala Leu Phe Phe Phe Asp
340 345 350

Ile Asp Leu Leu Leu Gln Arg Gly Pro Gln Tyr Ser Glu His Pro Thr
355 360 365

Phe Thr Ser Gln Tyr Arg Ile Gln Gly Lys Leu Glu Tyr Arg His Thr
 370 375 380

Trp Asp Arg His Asp Glu Gly Ala Ala Gln Gly Asp Asp Asp Val Trp
 385 390 395 400

Thr Ser Gly Ser Asp Ser Asp Glu Glu Leu Val Thr Thr Glu Arg Lys
 405 410 415

Thr Pro Arg Val Thr Gly Gly Gly Ala Met Ala Gly Ala Ser Thr Ser
 420 425 430

Ala Gly Arg Lys Arg Lys Ser Ala Ser Ser Ala Thr Ala Cys Thr Ala
 435 440 445

Gly Val Met Thr Arg Gly Arg Leu Lys Ala Glu Ser Thr Val Ala Pro
 450 455 460

Glu Glu Asp Thr Asp Glu Asp Ser Asp Asn Glu Ile His Asn Pro Ala
 465 470 475 480

Val Phe Thr Trp Pro Pro Trp Gln Ala Gly Ile Leu Ala Arg Asn Leu
 485 490 495

Val Pro Met Val Ala Thr Val Gln Gly Gln Asn Leu Lys Tyr Gln Glu
 500 505 510

Phe Phe Trp Asp Ala Asn Asp Ile Tyr Arg Ile Phe Ala Glu Leu Glu
 515 520 525

Gly Val Trp Gln Pro Ala Ala Gln Pro Lys Arg Arg Arg His Arg Gln
 530 535 540

Asp Ala Leu Pro Gly Pro Cys Ile Ala Ser Thr Pro Lys Lys His Arg
 545 550 555 560

Gly